PD-103 versus I-125 Plaque: Comparison of 319 Cases
The American Brachytherapy Society (ABS) consensus guidelines for plaque radiation therapy of choroidal melanoma suggests all centers perform preoperative comparative dosimetry prior to selecting which seeds or sources are used for treatment. Thus, the relative radiation dose to critical structures (e.g. tumor, macula, optic nerve, lens and globe) should be considered for this choice.
In this paper, investigators reviewed such comparisons for 319 consecutive cases of choroidal melanoma treated at The New York Eye Cancer Center and related hospitals. They also found that palladium-103 plaque were used in 98.7% of cases.
For equivalent tumor doses, the use of palladium-103 plaques resulted in mean reductions in irradiation of critical intraocular tissues responsible for vision preservation.
Therefore, informed by these comparisons, the doctors at The New York Eye Cancer Center and related hospitals decided to use iodine-125 plaque for only 4 (1.3%) of patients.
This study also revealed that tumor size and intraocular location effected the total radiation dose to the macula, optic nerve, lens and globe. However, this is the first large clinical dosimetry study comparing these two methods of plaque treatment. It supports the use of palladium-103 versus iodine-125 plaque therapy for almost all patients with choroidal melanoma.
Click here for a link to an open access copy of this paper
Receive the latest news and opportunities from The Eye Cancer Foundation. Please fill out the form below.
In this paper, investigators reviewed such comparisons for 319 consecutive cases of choroidal melanoma treated at The New York Eye Cancer Center and related hospitals. They also found that palladium-103 plaque were used in 98.7% of cases.
For equivalent tumor doses, the use of palladium-103 plaques resulted in mean reductions in irradiation of critical intraocular tissues responsible for vision preservation.
Therefore, informed by these comparisons, the doctors at The New York Eye Cancer Center and related hospitals decided to use iodine-125 plaque for only 4 (1.3%) of patients.
This study also revealed that tumor size and intraocular location effected the total radiation dose to the macula, optic nerve, lens and globe. However, this is the first large clinical dosimetry study comparing these two methods of plaque treatment. It supports the use of palladium-103 versus iodine-125 plaque therapy for almost all patients with choroidal melanoma.
Click here for a link to an open access copy of this paper
Receive the latest news and opportunities from The Eye Cancer Foundation. Please fill out the form below.